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ABSTRACT
CD44 plays a role in the progression of tumors and is expressed in cancer 
stem cells (CSCs). However, the mechanisms underlying the crosstalk of CD44 with 
stemness genes in CSC maintenance remains unclear. In this study, we demonstrated 
how the cleaved intracellular domain of CD44 (CD44ICD) activates stemness factors 
such as Nanog, Sox2 and Oct4, and contributes to the tumorigenesis of breast 
cancer. We have found that the overexpression of CD44ICD increased mammosphere 
formation in breast cancer cells. Treatment with a γ-secretase inhibitor (GSI), 
which blocks the cleavage of CD44ICD, interfered with mammosphere formation. 
Interestingly, CD44ICD decreased the expression levels and nuclear localization of 
stemness factors, but overexpression of CD44ICD reversed these effects. In addition, 
we showed that nuclear localization of CD44ICD is important for transcriptional 
activation of the stemness factors. Furthermore, CD44ICD-overexpressed cells 
exhibited strong tumorigenecity and greater metastatic potential than did the control 
cells or CD44-depleted cells in vivo in mice models. Taken together, it was supposed 
that CD44 promotes tumorigenesis through the interaction and nuclear-translocation 
of its intracellular domain and stemness factors. We suggest that the prevention of 
cleavage and nuclear-translocation of CD44ICD is a potential target in treating breast 
cancer.
INTRODUCTION
CD44, a receptor that binds to hyaluronic acid 
(HA), is a multistructural and multifunctional molecule 
and is responsible for cell-to-cell communication and 
that between the cells and extracellular matrix (ECM) 
[1]. CD44 is able to alter tumor environments through 
its involvement in cell trafficking, lymph node homing, 
and the coordination of cytokines and growth factor 
signaling [2]. As a major glycosaminoglycan in the ECM, 
HA accumulates at sites of cell division and rapid matrix 
remodeling, as is seen during tumorigenesis. HA activates 
signaling by binding to CD44 variants (CD44v), which 
result from the alternate splicing of the CD44 gene. [3, 
4]. However, the intracellular domain was equal to all 
CD44 variants [5]. The smallest form of CD44, designated 
standard CD44 (CD44s), is abundantly expressed in both 
normal and cancer cells, whereas the CD44v, which 
contain a variable number of exon insertions (v1–v10), 
are mostly expressed in cancer cells. The involvement 
of CD44v, especially CD44v4–v7 and CD44v6–v9, in 
tumor progression, has been reported in multiple clinical 
studies. In contrast, other studies have reported that CD44 
suppresses breast and prostate cancers [6, 7] and found 
no correlation between levels of CD44 expression and 
cancer progression [8]. CD44 can also react with other 
molecules, including collagen, fibronectin, osteopontin, 
growth factors and matrix metalloproteinases (MMPs), but 
the functional importance of these interactions is less well 
known [1]. It has also been reported that CD44 is involved 
in intracellular signaling through interactions with 
neighboring receptors, such as tyrosine kinase receptors, 
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in many types of cancers [9, 10]. Moreover, cleaved CD44 
intracellular domain translocates into the nucleus and acts 
as a signaling molecule [11].
Recently, CD44 has been extensively used as a 
surface marker to isolate cancer stem cells (CSCs) from 
breast, prostate, pancreas, ovarian and colorectal cancers 
[12]. In combination with other surface markers, CD44 can 
also discriminate between a variety of cancer subsets [13]. 
CD44-positive cells promote tumorigenesis in breast and 
colorectal cancers, displaying stem cell properties, such as 
self-renewal and differentiation. However, the correlation 
of CD44 expression levels with cancer prognosis and the 
utility of CD44 as a CSC marker are debatable [14–16]. 
Differential levels of CD44 expression may account for 
these discrepancies in the literature and contribute to 
the ambiguity regarding the functional aspects of CD44. 
Moreover, there is a lack of clarity regarding the function 
of CD44 in CSC maintenance and the mechanisms 
underlying its crosstalk with stemness genes.
Therefore, we undertook this study to detect the 
ability of CD44 expression to induce mammosphere 
formation. The mammosphere formation assay can enrich 
the population of cancer stem cells [17]. Specially, we 
focused on the function of the CD44 intracellular domain 
(CD44ICD) with regards to breast cancer stemness. 
Additionally, we identified the molecular mechanism 
whereby CD44ICD regulates stemness factors such 
as Nanog, Sox2, and Oct4, to maintain CSCs and to 
contribute to the tumorigenesis of breast cancer.
RESULTS
Detection of CD44 expression in six breast 
cancer cell lines
We measured the mRNA levels of CD44 and 17 kDa 
cleaved CD44ICD respectively by RT-PCR and western 
blot analysis (Figure 1A), as well as by evaluating their 
surface expression using a FACS analysis in six breast 
cancer cell lines (Figure 1B). Whereas the CD44 surface 
expression was detected in five cell lines but not in 
ZR-75–1 cells, among the six breast cancer cell lines, 
cleaved CD44ICD was strongly detected in the MCF-
7, T47D, JIMT and MDA-MB-231 cell lines. We also 
measured the expression levels of stemness factors, such 
as Nanog, Sox2, and Oct4, in these breast cancer cell 
lines (Figure 1A). The expression of Nanog and Oct4 
was not different between cells, whereas Sox2 was highly 
expressed in MCF-7 and MDA-MB231 cells. We then 
analyzed the mammosphere formation ability in six cell 
Figure 1: Basal expression levels of CD44 in breast cancer cell lines and mammosphere formation. (A) The basal expression 
levels of Nanog, Sox2, Oct4, and CD44 were detected with an RT-PCR (left panel) and western blot (right panel) analysis, respectively. 
GAPDH was used as a loading control. (B) CD44 levels were measured using a FACs analysis. (C) The mammosphere forming ability 
was measured under sphere forming conditions for 15 days as described in “materials methods”. All experiments were performed in the 
indicated breast cancer cell lines.
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lines (Figure 1C). Interestingly, mammospheres were 
readily formed by MCF-7, JIMT, and MDA-MB-231 cells, 
suggesting that there is a correlation of the mamosphere 
formation with the expression level of cleaved CD44ICD, 
rather than with CD44 surface expression.
Effect of overexpression of CD44ICD in the 
absence of CD44 on the potential of breast 
cancer cells for mammosphere formation
To test whether CD44ICD regulates the potential 
of breast cancer cells for mammosphere formation, we 
selected MDA-MB-231 and MCF-7 cells and generated 
stable cell lines, including CD44-depleted cells (CD44KD), 
CD44-depleted cells with overexpression of CD44ICD 
(CD44KD/ICDover), and wild-type cells with overexpression 
of CD44ICD (ICDover), using a lentiviral vector with a 
genotype that was confirmed by RT-PCR (upper panel) and 
western blotting (lower panel) (Supplementary Figure S1). 
These cells were mammosphere-cultured for 15 days 
(Figure 2A and 2B). The size and number of mammospheres 
were significantly reduced in CD44-depleted MDA-
MB-231 and MCF-7 cells. However, CD44-depleted and 
CD44ICD-overexpressed cells showed an increased size 
and number of mammospheres. Additionally, the size and 
number of spheres were greater in cells with CD44ICD 
overexpression than in wild-type (WT) cells. Treatment 
with GSI also significantly inhibited the formation of 
mammospheres in MCF-7 cells (Supplementary Figure S2). 
We also determined that the cell proliferation of breast 
cancer MDA-MB231 and MCF-7 cells was significantly 
reduced by CD44 ablation (Figure 2C). Taken together, our 
results suggest that CD44ICD might regulate mammosphere 
formation in breast cancer cells.
Figure 2: Overexpression of CD44ICD in the absence of CD44 increases the ability of mamosphere formation in 
breast cancer cells. (A) The mammosphere-forming ability of the indicated stable lines was measured under sphere forming conditions 
for 15 days. (B) The number of spheres was quantified in the experiments (A) (C) Cells were transfected with scRNA and CD44 siRNA. 
Following transfection, the cells were incubated for 48 hr, and cell proliferation was detected with a WST assay. (D) and (E) Cells were 
transfected with control and Oct4 expression vectors (D), and with control and Oct4 expression vectors (E) Following transfection, the cells 
were incubated for 48 hr, and the cell proliferation detected with a WST assay. The data are presented as the mean ± SD (n = 3). Significant 
differences are indicated by an asterisk (*p < 0.05), and the p values were calculated using the Student’s t test.
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Effect of CD44 on the expression of the stemness 
factors, Nanog, Sox2, and Oct4
To measure the expression levels of Nanog, Sox2 
and Oct4 in the absence of CD44, we first obtained three 
kinds of shRNA for CD44 and confirmed their complete 
silencing effect on CD44 in both MDA-MB-231 and 
MCF-7 cells (Supplementary Figure S3). Compared 
to the expression in control or scRNA transfected cells, 
we observed down-regulation of the mRNA and protein 
levels of Nanog, Sox2, and Oct4 in MDA-MB-231 and 
MCF-7 cells that had undergone CD44 knockdown 
by CD44 siRNA (Figure 3A). Moreover, treatment 
with a GSI, which blocks the cleavage of CD44ICD 
[18], did not change CD44 mRNA expression levels 
and reduced the cleaved CD44ICD protein levels. It 
also reduced the mRNA and protein levels of Nanog, 
Sox2, and Oct4. Moreover, the proliferation of CD44-
ablated MDA-MB-231 and MCF-7 cells was rescued 
by Oct4 overexpression (Figure 2D). The proliferation 
of Oct4-ablated cells was also rescued by CD44ICD 
overexpression (Figure 2E) in both MDA-MB-231 and 
MCF-7 cells. These results suggest that the cleavage of 
the intracellular domain of CD44 might influence the 
expression of stemness factors to maintain breast cancer 
stem cells.
Effect of the nuclear-translocation of cleaved 
CD44ICD on the expression and nuclear-
localization of Nanog, Sox2, and Oct4
We studied the localization of Nanog, Sox2, 
and Oct4 by preparing cytosolic and nuclear fractions 
of CD44-depleted MDA-MB-231 and MCF-7 cells 
(Figure 3B). In CD44-depleted MDA-MB-231 and 
MCF-7 cells, the expression of these stemness factors in 
the cytosolic fraction was similar to or greater than that 
observed in control cells treated with scrambled RNA. 
However, the expression of these factors was remarkably 
reduced in the nuclear fraction, as was the expression of 
cleaved CD44ICD (Figure 3B). These findings suggest 
that CD44 depletion inhibits the nuclear localization of 
Nanog, Sox2, and Oct4. We also blocked the nuclear 
translocation of CD44ICD using GSI treatment and 
detected the nuclear localization of stemness factors 
(Figure 3C). Following GSI treatment, both cytosolic 
and nuclear CD44ICD expression were significantly 
decreased in a time-dependent manner in both MDA-
MB-231 cells and MCF-7 cells, suggesting that GSI 
treatment blocked the cleavage and nuclear translocation 
of CD44ICD. Interestingly, the expression of Nanog, 
Sox2 and Oct4 in the nuclear fraction decreased with 
GSI treatment, whereas their expression in the cytosolic 
fraction increased, suggesting that GSI treatment blocked 
the nuclear translocation of stemness factors as well as 
CD44ICD.
The effect of GSI treatment on the localization 
of the stemness factors was visualized with an 
immunocytochemical analysis in both MDA-MB-231 
and MCF-7 cells (Figure 3D). In the absence of GSI, 
the expression of CD44ICD and the stemness factors 
was detected in both the nucleus and cytosol. Following 
GSI treatment, Nanog, Sox2, and Oct4 were significantly 
restricted to the cytosolic membrane, similar to CD44ICD 
localization. Taken together, these data suggest that the 
nuclear translocation of cleaved CD44ICD is critical to 
the nuclear localization of the stemness factors, Nanog, 
Sox2, and Oct4.
Effect of overexpression of CD44ICD in the 
absence of CD44 on the expression and nuclear 
localization of Nanog, Sox2, and Oct4
The overexpression of CD44ICD in CD44-depleted 
cells significantly increase the mRNA and protein 
expression levels of the stemness factors, which were 
similar to those in the cells with overexpression of full-
length CD44 (Figure 4A). To detect the effect on another 
molecules by GSI, because GSI also blocks cleavage 
of other molecules, such as Notch and ErB-4 [19], we 
evaluated the effect of GSI on the nuclear localization of 
these stemness factors following CD44ICD overexpression 
(Figure 4A). Whereas GSI reduced the expression of these 
stemness factors, GSI did not affect the expression of 
the same stemness factors following overexpression of 
CD44ICD, suggesting that the GSI effect on the expression 
of stemness factor is dependent on CD44ICD.
The localization of Nanog, Sox2, and Oct4 
was also evaluated in the context of overexpression 
of CD44ICD in CD44-depleted MDA-MB-231 and 
MCF-7 cells (Figure 4B). Their expression levels were 
primarily reduced in the nuclear fraction of CD44-
depleted cells, whereas they were increased in both the 
cytosolic and nuclear fractions by the overexpression of 
full-length CD44 or the overexpression of CD44ICD in 
CD44-depleted cells. As expected, GSI did not influence 
the localization of the stemness factors in CD44ICD-
overexpressed and CD44-depleted cells. The increased 
nuclear accumulation of Nanog, Sox2, and Oct4 following 
the overexpression of CD44ICD was visually confirmed 
using immunocytochemistry (Supplementary Figure S4). 
The overexpression of CD44ICD strongly promoted the 
nuclear localization of the stemness factors and their co-
localization with CD44ICD. These results suggest that the 
nuclear localization of Nanog, Sox2, and Oct4 is regulated 
by CD44ICD.
We further prepared the cleavage site truncated 
mutant CD44 (CD44_Mut), which cannot release cleaved 
CD44ICD, and overexpressed it in MDA-MB-231 
and MCF-7 cells to detect its influence on the nuclear 
localization of the stemness factors (Figure 4C). Whereas 
the overexpression of CD44 induced the expression of 
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Figure 3: CD44-depletion reduces both the expression and nuclear localization of the stemness factors, Nanog, Sox2, 
and Oct4. MDA-MB-231 and MCF-7 cells were transfected with scrambled siRNA (scRNA) and CD44 siRNA, and then treated with 
5 μM of GSI for 24 hr. (A) mRNA (upper) and protein levels (lower) of CD44 and stemness factors were detected with an RT-PCR and 
western blot analysis. (B and C) the changes in the localization of cleaved CD44ICD and stemness factors were detected using western blot 
analysis. The cells were treated with 5 μM of GSI for the indicated times. GAPDH and Lamin A/C were used as loading controls. (D) The 
changes in the localization of CD44ICD and its co-localization with stemness factors were detected during treatment with 2 μM of GSI for 
12 hr in MDA-MB-231 and MCF-7 cells using an immunocytochemical analysis as described in “materials methods”.
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these stemness factors in both the cytosol and nucleus, 
the overexpression of CD44_Mut did not significantly 
influence the expression of the stemness factors in either 
the nucleus or the cytosol fractions. Taken together, these 
results suggest that the cleavage and nuclear translocation 
of CD44ICD is critical for the nuclear localization of the 
stemness factors.
Effect of the C-terminal of CD44ICD on its 
interaction with Nanog, Sox2, and Oct4
Next, we performed an immunoprecipitation assay 
and investigated whether CD44ICD interacted directly 
with Nanog, Sox2, and Oct4 using MDA-MB-231 
cell lysates (Figure 5A). We generated an N-terminal 
truncated mutant CD44-ICD expressing vector (ICD_
ΔN35), and a NLS truncated mutant construct, CD44-
ICD_ΔN17, because the NLS of CD44ICD is located in 
the N-terminal region [20] and the C-terminal truncated 
mutant CD44ICD_ΔC19, as indicated in Figure 5B. We 
then, co-transfected these mutant vectors and Sox2- or 
Oct4-expressing vectors to detect their interaction site. 
The C-terminal truncated mutant CD44ICD_ΔC19 
did not interact with Sox2 and Oct4 (Figure 5B). This 
suggests that the essential region for the interaction 
with Sox2 and Oct4 is located in the C-terminal region 
of CD44ICD, including the PDZ domain [5]. We 
overexpressed the C-terminal truncated mutant CD44IC_
ΔC19 and fractionated the nucleus and cytosol (Figure 
5C). As expected, the reduced nuclear localization of 
both CD44ICD and the stemness factors following 
the overexpression of the C-terminal truncated mutant 
CD44IC_ΔC19 was detected in MDA-MB-231 and MCF-
7 cells (Figure 5C). Taken together, our results suggest 
Figure 4: Overexpression of CD44ICD in CD44-depleted cells increases both the expression and nuclear-localization 
of the stemness factors, Nanog, Sox2, and Oct4. Endogenous CD44 stable knockdown MDA-MB-231 and MCF-7 cells were 
transfected with the control vector and with the full-length CD44 and CD44ICD expression vectors. CD44ICD transfected cells were 
treated with 5 μM of GSI for 24 hr. (A) The mRNA (upper) and protein levels (lower) of CD44 and stemness factors were detected with 
an RT-PCR and western blot analysis. (B) The changes in the localization of CD44ICD and stemness factors were detected with a western 
blot analysis. GAPDH and Lamin A/C were used as loading controls. (C) Endogenous CD44 stable knockdown MDA-MB-231 and MCF-7 
cells were transfected with the control and full-length form of CD44, and with the cleavage site truncated mutant CD44 vector. The changes 
in the localization of CD44ICD and stemness factors were detected with a western blot analysis.
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that CD44ICD regulates the nuclear localization and 
transcriptional activation of stemness factors through an 
interaction with its C-terminal domain.
Effect of overexpression of CD44ICD in 
the absence of CD44 on the transcriptional 
activation of Sox2 and Oct4
We measured the luciferase activity of the Sox2 
and Oct4 promoter reporters to check whether CD44ICD 
also regulates the transcriptional activation of Sox2 
and Oct4 (Figure 6A). In control cells, transcriptional 
activation of the Sox2 promoter (left graph) and the 
Oct4 promoter (right graph) was repressed by both GSI 
and CD44 siRNA treatment (diagonal bars in Figure 
5A). The overexpression of CD44ICD enhanced the 
transcriptional activation of the Sox2 and Oct4 promoters 
more than in control cells. In CD44-depleted stable 
cells, the overexpression of CD44ICD alone induced the 
transcriptional activation of Sox2 and Oct4 more than 
in cells that overexpressed the full-length form of CD44 
(solid bars in Figure 5A).
We also over-expressed CD44-ICD_ΔN17 and the 
C-terminal truncated mutant CD44IC_ΔC19 (Figure 6B) 
and measured the luciferase activity of the Sox2 and 
Oct4 promoters (Figure 6C and 6D). Interestingly, 
the transcriptional activation of the Sox2 promoter 
(left graph) and the Oct4 promoter (right graph) was 
not influenced by transfection with CD44ICD_ΔN17 
(Figure 6C). In addition, the transcriptional activation of 
the Sox2 and Oct4 promoters was not enhanced when 
transfected with CD44ICD_ΔC19 compared to the 
transcriptional activation in the cells that overexpressed 
CD44ICD (Figure 6D). It suggests that the NLS region 
of CD44ICD for the nuclear localization of CD44 and 
the interaction between CD44ICD and stemness factors 
are important to the transcriptional activation of Sox2 
and Oct4.
Figure 5: CD44ICD interacts with the stemness factors, Nanog, Sox2, and Oct4 and regulates the nuclear-localization. (A) 
MDA-MB-231 cells were transfected with CD44ICD. The interaction between CD44 and Nanog, Sox2, and Oct4 were detected with an 
immunoprecipitation assay described in “materials and methods”. (B) HEK293 cells were transfected with CD44ICD or the truncated 
mutant constructs, ICD_ΔN17, ICD_ΔN35, ICD_ΔC19, and co-transfected with Sox2 and Oct4 expression vectors for 36 hr as described in 
“materials methods”. Their interaction was detected with an immunoprecipitation assay. (C) Endogenous CD44 stable knockdown MDA-
MB-231 and MCF-7 cells were transfected with the control and CD44ICD and C-terminal region truncated CD44 vectors. The changes in 
the localization of CD44ICD and stemness factors were detected by western blot. GAPDH and Lamin A/C were used as loading controls.
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Effect of overexpression of CD44ICD in the 
absence of CD44 on breast cancer tumorigenesis 
and metastasis in vivo
To analyze the in vivo effect of CD44ICD on 
breast cancer tumorigenesis, we prepared stable cell lines 
(Figure 7C) and xenografted mice using the following cell 
types as previously used: CD44KD, CD44KD/ICDover and 
ICDover (Figure 7A and 7B). Whereas the xenografts with 
CD44-depleted MDA-MB-231 cells did not form tumors, 
the largest tumor burdens were detected in MDA-MB-231 
cells with CD44ICD overexpression. The overexpression 
of CD44ICD in CD44-depleted MDA-MB-231 cells also 
promoted tumor growth in xenografted mice as well as 
in control cells. Furthermore, the CD44-depleted stable 
cells did not form tumors in additional xenografts using 
different cell numbers (Table 1).
We also injected the cells into the tail veins of mice, 
and detected colonies of tumor cells in their lungs (Figure 7D 
and 7E). While we rarely detected colonies of CD44-depleted 
MDA-MB-231 cells in mice lungs, colonies of MDA-
MB-231 cells with CD44ICD overexpression were detected 
frequently in mouse lungs. Colonies of MDA-MB-231 cells 
with CD44ICD overexpression and CD44-depletion were 
detected more frequently than colonies of CD44-depleted 
cells. These results show that the overexpression of CD44ICD 
strongly accelerates tumor progression and metastasis in mice 
in vivo, a similar finding to our in vitro results.
Figure 6: Overexpression of CD44ICD increases the transcriptional activation of the stemness factors, Sox2, and 
Oct4. (A) The transcriptional activation was measured with a reporter assay in wild-type (diagonal bars) and CD44KD MCF-7 (solid 
bars) cells. Cells were transfected with a Sox2 and Oct4 reporter vector alone or co-transfected with CD44 siRNA, CD44 or CD44ICD 
expression vectors. Following transfection, the cells were incubated for 12 hr and a vehicle (-) or 5 μM of GSI (+) were added. The 
cells were incubated for an additional 24 hr. The transcriptional activity was measured by luciferase activity described in “materials and 
methods”. (B) The expression of CD44ICD or of the truncated mutant constructs, ICD_∆N17 and ICD_∆C19 were detected with a western 
blot. (C) MCF-7 cells were transfected with the reporter vector alone or co-transfected with CD44-ICD or CD44-ICD_ΔN17 expression 
vectors for 36 hr. The luciferase activity was measured as described in “materials methods”. (D) MCF-7 cells were transfected with 
the reporter vector alone or co-transfected with CD44ICD or CD44ICD_ΔC19 expression vectors for 36 hr. The luciferase activity was 
measured. The data are presented as the mean ± SD (n = 3). Significant differences are indicated by an asterisk (*p < 0.05), and the p values 
were calculated using the Student’s t test.
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Figure 7: Overexpression of CD44ICD in CD44-depleted cells increased tumorigenesis and metastasis in breast cancer 
cells in xenograft mice in vivo. (A and B) The indicated stable lines of MDA-MB-231 cells (1 × 103) were implanted into nude mice to 
form subcutaneous xenografts, as described in “materials methods”. After 21 days, the tumors were isolated and the size and weight of those 
measured are presented in a statistical graph (A) and in a photograph (B). (C) The knockdown of CD44 and overexpression of CD44ICD 
were confirmed with an RT-PCR (upper panel) and western blot analysis (lower panel) in MDA-MB-231 cells. (D and E) The indicated 
stable lines of MDA-MB-231 cells (1 × 106) were injected into the tail veins of nude mice, as described in “materials methods”. After 21 
days, the lungs were isolated and the node numbers were counted; they are presented in a statistical graph (D) and in a photograph (E). The 
data are presented as the mean ± SD (n = 5). A statistical analysis was performed using a one-way ANOVA, and significant differences are 
indicated by an asterisk (*p < 0.0001).
Table 1: Overexpression of CD44ICD in CD44-depleted MDA-MB-231 cells increases lung 
metastasis in mice. The indicated stable lines of MDA-MB-231 cells (1 × 106) were injected into the tail veins of nude 
mice as described in “material and methods”. After 21 days, the lungs were isolated and the number of mice with tumor node 
bearing lungs was counted.
MDA-MB-231 Tumorigenesis Metastasis
103 Cells 104 Cells 105 Cells 106 Cells
Wild Type 4/5 5/5 5/5 4/5
CD44KD 2/5 2/5 3/5 0/5
CD44KD / ICDover 5/5 5/5 5/5 4/5
CD44 ICDover 5/5 5/5 5/5 5/5
The cells were derived from spheres
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DISCUSSION
In this study, we observed that the expression 
of cleaved CD44ICD in breast cancer cells is an active 
regulator of mammosphere formation. We used a serum-
free non-adherent culture technique, as used in previous 
studies [21]. whereas most cells died after being plated 
onto the non-adherent surface, those that survived 
formed spherical colonies termed mammospheres and 
the enriched cells were shown to be stem cells. This 
suggested that the cleavage of CD44ICD potentially 
regulates cancer stemness characteristics, which led 
us to investigate the γ-secretase-dependent cleavage 
of CD44ICD. Several substrates for the presenilin-
dependent γ-secretase have recently been identified, 
including Notch, E-cadherin, ErbB-4, and a β-amyloid 
precursor protein [19]. This cleavage releases CD44ICD 
and allows its translocation into the nucleus. Nuclear 
CD44ICD regulates transcriptional activation through 
several transcriptional factors, such as CBP/p300 and 
STAT3 [22]. There is also evidence that the full-length 
form of CD44 translocates into the nucleus and activates 
STAT3 [23]. Therefore, we overexpressed CD44ICD 
alone in CD44-depleted cells. The overexpression of 
CD44ICD enhanced both mammosphere formation and 
the expression of the stemness factors, Nanog, Sox2 
and Oct4. The overexpression of CD44ICD containing a 
mutant NLS did not have these effects, suggesting that in 
addition to the requirement the full length form of CD44, 
the cleavage and nuclear translocation of CD44ICD is also 
important for the expression and activation of stemness 
factors.
Coordinated networks of stemness factors are 
the master regulatory mechanisms of pluripotency 
and differentiation in stem cells. Stem cell-specific 
transcription factors, such as Nanog, Sox2 and 
Oct4 alone and in combination have been studied in 
embryonic stem (ES) cell pluripotency and cancer stem 
cell formation [24]. For example, Nanog overexpression 
enables the propagation of mouse ES cells [25]. 
Although Nanog is not required for the establishment 
of pluripotency in ES cells, it does maintain the self-
renewal capacity of these cells, and its expression 
has been shown to suppress differentiation. Sox2 is a 
member of the SRY-related HMG box (Sox) transcription 
factor family [26]. Sox2 remains less well characterized 
than either Oct4 or Nanog, but Sox2 is known to play a 
major role in the regulation of stem cell fate. Moreover, 
the down-regulation or overexpression of Oct4 
leads to a loss of pluripotency in ES cells as the cells 
differentiate [27, 28]. This suggests that precise levels 
of Oct4 are required for the maintenance of stem cell 
pluripotency. Additionally, it is clear that these stemness 
factors function collaboratively to regulate the state of 
differentiation of ES cells. Sox2 and Oct4 are known 
to act synergistically to regulate their own transcription 
as well as the expression of other key stem cell genes, 
including NANOG [2]. These stemness factors also 
co-occupy genes and share a substantial fraction of 
target genes. About half of the promoter regions bound 
by Oct4 has been shown to also be bound by Sox2 and 
Nanog [29]. Moreover, the binding sites of Nanog, Sox2 
and Oct4 are in close proximity to each other, further 
confirming that the proteins work in concert.
We also found that CD44ICD shares characteristics 
with Nanog, Sox2, and Oct4. Evidence of a direct 
interaction between the C-terminal region of CD44ICD 
and these stemness factors, and of the coordination of 
their nuclear translocation was observed. Previously, it 
was reported that HA stimulates the interaction of CD44v3 
interaction with Oct4-Sox2-Nanog, leading to complex 
formation and nuclear translocation [30]. The interaction 
between HA and CD44 mediates Nanog-Stat-3 signaling 
pathways that induce MDR1 expression and ankyrin/
cytoskeleton functions [31]. Others have investigated 
the interaction between CD44 and stemness factors and 
have suggested that HA regulates the CD44-mediated 
activation of stemness factors. We found the first piece 
of evidence of a direct interaction between the C-terminal 
region of CD44ICD and stemness factor transcription and 
their co-translocation into the nucleus. In our study, the 
overexpression of CD44ICD itself induced the nuclear 
translocation and transcriptional activation of stemness 
factors, suggesting that the activation of stemness factors 
and the maintenance of stemness by CD44ICD occurs 
in an HA-independent manner. However, more studies 
are needed to elucidate the HA-induced cleavage of 
CD44ICD and the interaction between CD44ICD and 
stemness factors, which might be important in tumor 
microenvironments.
Our results suggest that the expression of 
CD44 is important to the maintenance and possible 
acceleration of tumorigenesis through the cleavage 
of its intracellular domain and its interaction with 
stemness factors. CD44 has already been targeted in 
breast cancer therapy [2] using monoclonal antibodies 
[32] and HA-tagged drugs [33]. We propose that GSI 
shows potential in being used as an inhibitor of the 
cleavage of CD44ICD. To be used as a drug targeted 
to cancer stem cells, GSI would require an enhanced 
specificity to CD44ICD or to the interaction between 
CD44ICD and stemness factors, or both.
MATERIALS AND METHODS
Cell culture and transfection
The human breast cancer cell lines, MCF-7, T-47D, 
ZR-75–1, JIMT, SK-BR-3 and MDA-MB-231, were 
obtained from the ATCC and maintained in RPMI 1640 and 
Dulbecco’s Modified Eagle Medium (DMEM) with 10% 
fetal bovine serum (FBS) and 1% antibiotics (Invitrogen, 
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San Diego, CA). Cells cultures were maintained at 
37°C in an atmosphere of 5% CO2, as previously 
described [34]. Transfection with CD44, CD44ICD, 
the truncated mutant CD44ICD, Sox2, and Oct4 
expression vectors [35] as well as with CD44 siRNA was 
performed with Lipofectamine 2000 and Lipofectamine 
RNAiMAX reagents (Invitrogen), according to the 
reagent manufacturer’s instruction. CD44 siRNA #1 
(5′-UAUUCAAAUCGAUCUGCGCUU-3′) and CD44 
siRNA #2 (5′-GACCAAUUACCAUAACUAUU-3′) were 
purchased from Genolution. Cells were harvested two 
days after transfection for use in the experiments.
Mammosphere culture
Cells were grown in ultra-low attachment plates 
(Corning) and in Mammary Epithelium Basal Medium 
(MEBM; Lonza) supplemented with B27 (Gibco), 
20 ng/ml of EGF, and 20 ng/ml of bFGF (PeproTech) 
at a density of 1000 cells/ml. After culturing the cells 
for 15 days, we counted the mammospheres with 
diameters > 50 μm.
Cloning and generation of stable cell lines
The CD44 coding region (GenBank accession 
number NM_000610.3) was isolated and cloned into 
the pLECE3 lentiviral vector with an N-terminal Flag-
tag [36]. PCR analysis of cDNA was used to generate 
expression constructs of full-length CD44; CD44-ICD; 
and mutant constructs with a 17 amino acid truncation 
at the N-terminal (CD44ICD_ΔN17), 35 amino acid 
truncation at the N-terminal (CD44ICD_ΔN35), and 
19 amino acid truncation at the C-terminal (CD44ICD_
ΔC19), respectively, and an essential four amino acid 
(I287 ~ N290) truncation at the cleavage site (CD44_Mut) 
[11]. The primers are described in Supplementary 
Table S1. The PCR analysis was performed following the 
Ex-Taq manual (TaKaRa, Shiga, Japan). For subcloning, 
two restriction enzyme sites, Pac1 and Not1 (NEB), 
were incorporated into the primers and are underlined 
in Supplementary Table S1. The shRNA-expressing 
lentiviral vectors for the CD44 and Oct4 knockdown 
cells targeted 3′UTR and were purchased from Sigma. 
Lentivirus production and the generation of stable cell 
lines have been previously described [37].
Total RNA isolation and reverse transcriptase-
polymerase chain reaction
RNA isolation was performed with the TRIzol® 
Reagent (Invitrogen) according to the manufacturer’s 
instructions. Subsequently, we performed a reverse 
transcription PCR using a reverse transcription system 
(Promega). The primers are described in Supplementary 
Table S1. The PCR was performed following the Ex-Taq 
manual.
Luciferase assay
For the Sox2 and Oct4 reporter assays, Sox2 and 
Oct4 promoter constructs, pGL3-SRR2 [38] and phOct4-
Luc [35], were used. MCF-7 cells were transfected with 
the plasmids and a β-galactosidase expression vector for 
normalization. After 48 hr, the luciferase activity was 
measured using a luciferase assay system (Promega) 
according to the manufacturer;s instruction.
Fractionation of cellular extracts and western 
blotting
Nucleic and cytosolic extracts were prepared from 
MDA-MB-231 and MCF-7 cells following CD44 siRNA 
transfection and GSI treatment and from CD44KD MDA-
MB-231 and MCF-7 cells following CD44 or CD44-ICD 
overexpression, as described previously [39].
For western blotting, the cells were lysed in a RIPA 
buffer (Biosesang) containing a protease inhibitor cocktail 
(Sigma). The primary antibodies were anti-GAPDH, anti-
CD44, anti-Nanog, anti-Sox2, and anti-Oct4 and were 
purchased from Santa Cruz, as well as anti-FLAG, which 
was purchased from Sigma. The proteins of interest were 
detected using ECL solutions (Amersham Life Science) 
with a LAS-3000 (Fujifilm) detector according to the 
manufacturer’s directions.
Immunoprecipitation
Cell lysates were pre-cleared by being incubated 
with 20 μl of protein A/G-linked agarose beads (Santa 
Cruz) for 1 hr at 4°C. After spinning down the beads, 
the supernatant was incubated with 2 μg of a specific 
antibody (anti-FLAG, anti-CD44, anti-Nanog, anti-Sox2, 
and anti-Oct4) overnight at 4°C, followed by incubation 
with 40 μl of protein A/G-linked agarose beads for 1 hr. A 
mouse or rabbit IgG (Santa Cruz) was used as the negative 
control. Following the incubation, the beads were washed 
three times in a RIPA buffer before being dissolved in a 
SDS-PAGE loading buffer. A western blot analysis was 
performed as described elsewhere [40].
Cell proliferation analysis
Cells were grown in 96-well culture plates and 
transfected with CD44 siRNA or Oct4 and CD44-ICD 
expression vectors. After 48 hr, a WST solution (Daeil, 
Korea) was subsequently added to each well. After 1–3 hr 
of additional incubation, the absorbance was measured on 
and ELISA reader at a test wavelength of 450 nm.
Flow cytometric experiments
For the flow cytometric experiments, cells from the 
breast cancer cell lines (MCF-7, T47D, ZR-75–1, JIMT, 
SK-BR-3 and MDA-MB-231) were detached and washed 
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with PBS supplemented with 2% FBS. The following 
antibody was used: FITC-conjugated anti-human CD44 
(BD Pharmingen). Between 30,000 and 50,000 cells were 
incubated with the antibody for 30 min on ice. Following 
the wash, the cells were fixed with 4% paraformaldehyde 
at 4°C prior to analysis. A minimum of 10,000 events per 
sample were collected using the FACSDiva and Cell Quest 
applications (BD Biosciences).
Immunocytochemistry
CD44, Nanog, Sox2, and Oct4 were detected 
immunocytochemically in MDA-MB-231 and MCF-
7 cells after GSI treatment or CD44ICD transfection. 
The cells were fixed using 3% formaldehyde, blocked 
with 5% bovine serum albumin in phosphate buffered 
saline (PBS), and incubated with primary antibodies, 
including anti-CD44, anti-Nanog, anti-Sox2, and anti-
Oct4, diluted (1:200) in PBS. The cells were conjugated 
with the secondary antibodies labeled with FITC or Cy5 
(Invitrogen), diluted (1:200) in PBS. The samples were 
treated with mounting medium with 4′, 6-diamidino-2-
phenylindole and analyzed using an LSM 700 confocal 
microscope (Carl-Zeiss).
Animal experiments
All animal experiments were approved by the 
Institutional Review Board of the Yonsei University 
College of Medicine and were performed in specific 
pathogen-free facilities in accordance with the University’s 
Guidelines for the Care and Use of Laboratory Animals 
(2013–0018). The preparation of xenografted mice 
was performed as described previously [41], as was the 
preparation of lung metastasized mice [40].
Statistical analysis
Two tumors per mouse were obtained and analyzed 
to obtain the mean tumor volume per mouse. Unpaired t-
tests were used to analyze the mean tumor volume of the 
xenografted mice. Statistical analyses were performed using 
the Student’s t-test. The data were considered statistically 
significant for p-values of < 0.05. Statistical analyses were 
performed using the GraphPad Prism software (version 6; 
GraphPad Software Inc., La Jolla, CA).
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